Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2021 | Outcomes and management of patients with R/R myeloma who progress on bispecific antibodies

Tarek H Mouhieddine, MD, Icahn School of Medicine at Mount Sinai, New York, NY, discusses the results of a study investigating the treatment options and outcomes of relapsed/refractory (R/R) patients with multiple myeloma following treatment with bispecific antibodies. Overall, the study found that patients who received another T-cell-directed therapeutic after progressing on a bispecific antibody had deep and durable responses, with progression-free survival (PFS) averaging 28 months. This data suggests that sequential treatment with other T-cell-directed therapeutics such as chimeric antigen receptor (CAR) T-cells or bispecific antibodies is a feasible and promising option for this patient population. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.